tiprankstipranks
Trending News
More News >
Cipher Pharmaceuticals (CPHRF)
OTHER OTC:CPHRF
US Market
Advertisement

Cipher Pharmaceuticals (CPHRF) Earnings Dates, Call Summary & Reports

Compare
18 Followers

Earnings Data

Report Date
Nov 06, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
0.15
Last Year’s EPS
0.01
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 07, 2025|
% Change Since: 11.94%|
Earnings Call Sentiment|Positive
Cipher Pharmaceuticals showcased strong financial performance in Q2 2025, driven by the successful acquisition and integration of the Natroba business, leading to record-breaking revenue and significant EBITDA growth. However, challenges in the U.S. licensing segment and onetime legal costs moderated the overall positive outcomes.
Company Guidance -
Q3 2025
During the Q2 2025 conference call, Cipher Pharmaceuticals reported a record-breaking quarter for net revenue, driven primarily by the U.S. Natroba business, which generated $7.8 million in revenue, contributing to a total of $13.4 million for the quarter—a 152% increase from the previous year. The gross profit from Natroba was $6.6 million, with a gross margin of 86%, excluding non-cash adjustments. The base business also performed well, with Canadian product revenue growing by 12% to $4.1 million and contributing to an overall adjusted EBITDA of $7.6 million for the quarter. The company highlighted its fourfold growth strategy for Natroba, including expanding in the U.S., adding complementary products, launching in Canada, and out-licensing globally. Additionally, Cipher executed a $15 million debt repayment and utilized $2.1 million for share repurchases, while maintaining $11.3 million in cash and $25 million in debt, positioning itself for further strategic growth opportunities.
Record-Breaking Revenue
Cipher Pharmaceuticals' Q2 2025 yielded the highest earnings quarter for total net revenue in the company's history, primarily driven by the U.S. Natroba business.
U.S. Natroba Business Performance
The Natroba business generated $7.8 million in revenue in Q2 2025, leading to a strong gross margin of 86% and contributing significantly to the company's record earnings.
Growth in Canadian Product Portfolio
Canadian product portfolio revenue increased by 12% in Q2 2025 compared to the same quarter last year.
Total Adjusted EBITDA Growth
Adjusted EBITDA for Q2 2025 was $7.6 million, a 148% increase compared to the same quarter in 2024.
Significant Debt Reduction
Cipher allocated $15 million to repay its revolving credit facility and utilized $2.1 million for share repurchases, further reducing its debt balance to $18 million.
State of Illinois Favorable Development
Natroba was made the preferred product for scabies treatment under Medicaid in Illinois, setting a precedent for potential similar approvals in other states.

Cipher Pharmaceuticals (CPHRF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CPHRF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 06, 2025
2025 (Q3)
0.15 / -
0.01
Aug 07, 2025
2025 (Q2)
0.16 / 0.22
0.1283.33% (+0.10)
May 08, 2025
2025 (Q1)
0.11 / 0.10
0.2-50.00% (-0.10)
Mar 18, 2025
2024 (Q4)
0.19 / 0.13
0.3-56.67% (-0.17)
Nov 07, 2024
2024 (Q3)
0.14 / 0.01
0.27-96.30% (-0.26)
Aug 08, 2024
2024 (Q2)
0.12 / 0.12
0.120.00% (0.00)
May 09, 2024
2024 (Q1)
0.10 / 0.20
0.1100.00% (+0.10)
Mar 14, 2024
2023 (Q4)
0.10 / 0.30
0.78-61.54% (-0.48)
Nov 09, 2023
2023 (Q3)
0.07 / 0.27
0.1170.00% (+0.17)
Aug 10, 2023
2023 (Q2)
0.09 / 0.12
0.0850.00% (+0.04)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CPHRF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 07, 2025
$9.80$11.37+16.02%
May 08, 2025
$10.54$9.97-5.41%
Mar 18, 2025
$8.37$9.43+12.66%
Nov 07, 2024
$11.08$10.03-9.48%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cipher Pharmaceuticals (CPHRF) report earnings?
Cipher Pharmaceuticals (CPHRF) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).
    What is Cipher Pharmaceuticals (CPHRF) earnings time?
    Cipher Pharmaceuticals (CPHRF) earnings time is at Nov 06, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CPHRF EPS forecast?
          CPHRF EPS forecast for the fiscal quarter 2025 (Q3) is 0.15.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis